Notable Upgrades: Corcept Therapeutics (CORT), Impax Laboratories (IPXL), Tiffany & Co. (TIF), Inogen (INGN), Actavis plc (ACT)

Analysts at Piper Jaffray are out with a report this morning upgrading shares of Corcept Therapeutics Incorporated (CORT) with a ‘Overweight‘ from ‘Neutral‘ rating. The firm raised its price target for the company to $9.00 from $2.50. Corcept Therapeutics Inc. shares are currently priced at 24.62x next year’s forecasted earnings. Ticker has a forward P/E […] View the full post at: Notable Upgrades: Corcept Therapeutics (CORT), Impax Laboratories (IPXL), Tiffany & Co. (TIF), Inogen (INGN), Actavis plc (ACT) Related posts: Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock Caterpillar Inc. Downgraded to “Neutral” at BofA